THANZ/LinkedIn
Mar 13, 2026, 16:15
New Evidence From the COBRRA Trial in Acute VTE – THANZ
Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) shared a post on LinkedIn about a recent article by Lana A. Castellucci et al, published on NEJM:
“Congratulations to our THANZ members on a NEJM publication!
This international randomized trial (COBRRA) shows substantially lower bleeding risk with apixaban compared with rivaroxaban in acute VTE – evidence that matters at the bedside.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté
Read the Full Article on NEJM
Other posts featuring THANZ on Hemostasis Today.
-
Mar 13, 2026, 16:09Wolfgang Miesbach: Brussels Will Be the Perfect Stage for EAHAD 2027
-
Mar 13, 2026, 15:59Nicola Pozzi: A Brand-New Mechanism to Reduce Thrombosis Without Increasing Bleeding Risk
-
Mar 13, 2026, 15:47Heghine Khachatryan: Real-World Data on DOAC Use in Pediatric Oncology
-
Mar 13, 2026, 15:29Megan Adediran: Heavy Period as a Sign of a Underlying Bleeding Disorder
-
Mar 13, 2026, 15:28Gareth Owens: Preventing Aortic Dissection Through Post-Mortem Genetics Testing
-
Mar 13, 2026, 14:20Tareq Abadl: How One Blood Donation Saves Three Lives
-
Mar 13, 2026, 14:10Julie Cardoso: Bringing Clinicians Together to Improve VTE Detection and Treatment
-
Mar 13, 2026, 13:10Hisam Siddiqi: Is FFP Really The Magic Elixir of All Coagulopathies in Liver Disease
-
Mar 13, 2026, 13:08Lena Volland: Screening Gaps and Clinical Outcomes of Iron Deficiency Anemia in Pregnancy